HAPLN1

Across TCGA pan-cancer cohorts, HAPLN1 mass-spec protein differs between tumor and matched normal tissue in 5 of 18 cancer types tested, making tumor–normal expression one of HAPLN1’s most consistent transcriptional readouts.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where HAPLN1 mass-spec protein is more highly expressed in tumor relative to normal tissue. In most cancer types HAPLN1 is over-expressed in tumor, although a few such as COAD and HNSC show the opposite, repressed pattern.

CCRCC, COAD, and PDAC are the cancer types where HAPLN1 tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in HAPLN1 mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
CCRCC	Male	III,IV	+2.282	<.001	12	view →
COAD	Female	III,IV	−1.637	<.001	11	view →
PDAC	All	All	+0.963	<.001	8	view →
HNSC	All	All	−0.943	.004	6	view →
LSCC	All	All	+0.414	.006	4	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 5 strongest of 5 lineages.

HAPLN1–CCRCC

Open the CCRCC breakdown →